Momenta Pharma sets priority on launch of M-Enoxaparin, as losses narrow

The US biotechnology industry includes about 1,000 firms, with combined annual revenue close to $50.0 billion. Rapid advances in the sector mark the 2000s as the Biotechnology Era, with many aspects of life revolutionized during this period, say analysts at Beacon Equity Research. They highlight for comment Momenta Pharmaceuticals, a company specializing in the structural analysis of complex mixture drug, which applies its technology to the development of generic versions of complex drugs, as well as the discovery and development of novel compounds.

Momenta's products include M-Enoxaparin, a technology-enabled generic version of Sanofi-Aventis' Lovenox to prevent and treat deep vein thrombosis and support the treatment of acute coronary syndromes; and M356, a similarly developed copy of Teva's Copaxone (glatiramer), for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis.

Strong revenue growth